Swiss pharmaceutical company Santhera Pharmaceuticals Holding AG (SPHDF.OB) announced on Thursday a first-half net loss of 15.3 million Swiss Francs, an improvement from the previous year's net loss of 23.3 million francs.
The loss per share decreased to 1.35 francs, down from the previous year's 2.09 francs. The operating loss also narrowed, amounting to 17.7 million francs compared to 20.3 million francs in the prior year.
During the first half of 2024, revenue from contracts with customers increased to 14.1 million francs, up from 3.9 million francs in the same period last year.
Net sales reached 6.5 million francs, driven by the launch of AGAMREE in Germany and Austria, compared to 1.0 million francs last year, following the cessation of RAXONE sales due to its disposal.
Santhera also recognized 7.7 million francs from its partners in China and North America, reflecting milestone achievements and product supply, an increase from 3.0 million francs in the previous year.
